The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL: which method is superior?
Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a comprehensive analysis of PCR for BCR::ABL1 and next-generation sequencing (NGS)-based measurable residual disease (MRD) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), highlighting that NGS-based MRD is more sensitive and potentially more specific for the lymphoblast clone. However, Dr Short notes that both methods should be used when considering discontinuation of tyrosine kinase inhibitor (TKI) therapy. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
